Allogene Therapeutics, Inc.

we will be making certain forward-looking statements. These may include statements regarding the success and timing of our ongoing and planned clinical trials, data presentations, regulatory filings, future research and development efforts, manufacturing capabilities, and 2022 financial guidance, among other things. These forward-looking statements are based on current information, assumptions, and expectations that are subject to change. A description of the potential risks can be found in our earnings press release and latest SEC disclosure documents. You are cautioned not to place undue reliance on these forward-looking statements, and Allogene disclaims any obligation to update these statements. I'll now turn the call over to David.

Thank you, Christine, and good afternoon.

Since our last update, we have continued to make significant progress across our pipeline. from our lead CD19 candidate, Allo501A, and our lead PCMA candidate, Allo715, to our first thalassemia candidate, Allo316. We believe each of these programs have promising potential, and we remain focused on advancing these candidates in a way that will allow us to define, shape, and expand the future of cell therapies.